Her2-targeted drugs, including the humanized monoclonal antibody drug trastuzumab and its related antibody–drug conjugate (ADC), have been developed to treat Her2 positive (Her2+) breast cancer patients defined by the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP). The gene discussed is ERBB2; the disease is breast carcinoma.